Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study

• Kohei KakuKawasaki Medical School
• Kazuhiro YamamotoTottori University
• Yumiko FukushimaBoehringer Ingelheim (Japan)
• Seiko MizunoEli Lilly (Japan)
• Daisuke NittaBoehringer Ingelheim (Japan)